Afatinib was first found to suppress ATP-binding cassette subfamily G member 2 (ABCG2) activity, self-renewal capacity, and tumorigenesis in patient-derived leukemia cells—specifically, via ABCG2 promoter methylation [77]. Here, ABCG2 is linked to leukemia.